New TYSABRI® data show earlier treatment and longer-term use result in significant reductions in MS disease activity Biogen Idec, 3 Oct 2013 Accessed on 4 Oct 2013 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1861119. CommentRecommendBookmarkWatch